These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3916764)

  • 41. Combined effects of IL-12 and IL-18 on the clinical course and local cytokine production in murine pulmonary infection with Cryptococcus neoformans.
    Qureshi MH; Zhang T; Koguchi Y; Nakashima K; Okamura H; Kurimoto M; Kawakami K
    Eur J Immunol; 1999 Feb; 29(2):643-9. PubMed ID: 10064081
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunization of mice with stable, acapsular, yeast-like mutants of Cryptococcus neoformans.
    Fromtling RA; Kaplan AM; Shadomy HJ
    Sabouraudia; 1983 Jun; 21(2):113-9. PubMed ID: 6348975
    [TBL] [Abstract][Full Text] [Related]  

  • 43. T cell response to soluble cryptococcal antigens after recovery from cryptococcal infection.
    Hoy JF; Murphy JW; Miller GG
    J Infect Dis; 1989 Jan; 159(1):116-9. PubMed ID: 2462601
    [No Abstract]   [Full Text] [Related]  

  • 44. Induction of antigen-specific suppression by circulating Cryptococcus neoformans antigen.
    Murphy JW; Cox RA
    Clin Exp Immunol; 1988 Aug; 73(2):174-80. PubMed ID: 2460273
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pulmonary cryptococcosis: atypical results in the serum test for cryptococcal antigen.
    Jenkins C; Breslin AB
    Aust N Z J Med; 1982 Oct; 12(5):527-30. PubMed ID: 6758749
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cryptococcal meningitis; significance of positive antigen test on undiluted spinal fluid.
    Salom IL
    N Y State J Med; 1981 Aug; 81(9):1369-70. PubMed ID: 7022273
    [No Abstract]   [Full Text] [Related]  

  • 47. Innate host defenses against Cryptococcus neoformans.
    Hole C; Wormley FL
    J Microbiol; 2016 Mar; 54(3):202-11. PubMed ID: 26920880
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human defenses against Cryptococcus neoformans: an update.
    Brummer E
    Mycopathologia; 1998-1999; 143(3):121-5. PubMed ID: 10353206
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Experimental cryptococcosis in guinea pigs.
    Riera CM; Masih DT; Nobile R
    Mycopathologia; 1983 Jun; 82(3):179-84. PubMed ID: 6350885
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Fever of unknown origin and cryptococcal antigen].
    Torroba Alvarez L; Fortún Abete J; Buzón Rueda L; Moreno Caparrós A
    Med Clin (Barc); 1988 Oct; 91(13):514. PubMed ID: 3067009
    [No Abstract]   [Full Text] [Related]  

  • 51. Cryptococcus neoformans and cryptococcosis.
    Harrison TS
    J Infect; 2000 Jul; 41(1):12-7. PubMed ID: 11041708
    [No Abstract]   [Full Text] [Related]  

  • 52. Mechanisms of
    Casadevall A; Coelho C; Alanio A
    Front Immunol; 2018; 9():855. PubMed ID: 29760698
    [No Abstract]   [Full Text] [Related]  

  • 53. Fungicidal activity of IFN-gamma-activated macrophages. Extracellular killing of Cryptococcus neoformans.
    Flesch IE; Schwamberger G; Kaufmann SH
    J Immunol; 1989 May; 142(9):3219-24. PubMed ID: 2496162
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Capsular polysaccharides from a parent strain and from a possible, mutant strain of Cryptococcus neoformans serotype A.
    Bhattacharjee AK; Kwon-Chung KJ; Glaudemans CP
    Carbohydr Res; 1981 Sep; 95(2):237-48. PubMed ID: 7028261
    [No Abstract]   [Full Text] [Related]  

  • 55. Epidemiologic differences among serotypes of Cryptococcus neoformans.
    Bennett JE; Kwon-Chung KJ; Howard DH
    Am J Epidemiol; 1977 Jun; 105(6):582-6. PubMed ID: 326036
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced gamma interferon production through activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide in interleukin-18-deficient mice with systemic cryptococcosis.
    Kawakami K; Kinjo Y; Yara S; Uezu K; Koguchi Y; Tohyama M; Azuma M; Takeda K; Akira S; Saito A
    Infect Immun; 2001 Nov; 69(11):6643-50. PubMed ID: 11598033
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of macrophage inflammatory protein-1 alpha/CCL3 in regulation of T cell-mediated immunity to Cryptococcus neoformans infection.
    Olszewski MA; Huffnagle GB; McDonald RA; Lindell DM; Moore BB; Cook DN; Toews GB
    J Immunol; 2000 Dec; 165(11):6429-36. PubMed ID: 11086082
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Generation of antifungal effector CD8+ T cells in the absence of CD4+ T cells during Cryptococcus neoformans infection.
    Lindell DM; Moore TA; McDonald RA; Toews GB; Huffnagle GB
    J Immunol; 2005 Jun; 174(12):7920-8. PubMed ID: 15944298
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Naïve B cells reduce fungal dissemination in Cryptococcus neoformans infected Rag1
    Dufaud C; Rivera J; Rohatgi S; Pirofski LA
    Virulence; 2018 Jan; 9(1):173-184. PubMed ID: 28837391
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NK cells use perforin rather than granulysin for anticryptococcal activity.
    Ma LL; Wang CL; Neely GG; Epelman S; Krensky AM; Mody CH
    J Immunol; 2004 Sep; 173(5):3357-65. PubMed ID: 15322199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.